Leon Chen - May 6, 2021 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
Director
Signature
/s/ Christine Ring, as Attorney-in-Fact for Leon Chen
Stock symbol
NRIX
Transactions as of
May 6, 2021
Transactions value $
$0
Form type
4
Date filed
5/24/2021, 07:48 PM
Next filing
Jun 14, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRIX Director Stock Option (right to buy) Award $0 +17.5K $0.00 17.5K May 6, 2021 Common Stock 17.5K $27.38 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 6, 2022, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
F2 The Reporting Person is a partner of The Column Group which invests through The Column Group II, LP ("TCG II LP"), Ponoi Capital, LP ("Ponoi LP") and Ponoi Capital II, LP ("Ponoi II LP," and together with TCG II LP and Ponoi LP, the "Funds"), among other entities. Under the partnership agreements of the Funds, the Reporting Person is deemed to hold the stock option for the economic benefit of the Funds. The Funds may be deemed indirect beneficial owners of the stock option. The Reporting Person disclaims beneficial ownership of the stock option except to the extent of his pecuniary interest therein.